YORBA LINDA, Calif. (PRWEB) October 30, 2017
Interactions between tumor and immune cells in the tumor microenvironment (TME) play a key role in tumor progression and treatment response, with accumulating evidence indicating a crucial role for tumor infiltrating immune cells. Although infiltrating T cells have been correlated with improved clinical outcome, they are ineffective in eradicating tumors due to their inhibition by immune checkpoint molecules.
Immune checkpoint inhibitors have demonstrated therapeutic efficacy and durable response for several tumor types, including NSCLC. However, the majority of patients are resistant or relapse after initial response. Characterizing the TME for checkpoint expression with single-cell and spatial resolution can provide critical insight into new immunotherapeutic strategies and identify new predictive biomarkers for stratifying patients most likely to benefit from immunotherapies.
Through this webinar, which is sponsored by Advanced Cell Diagnostics, participants will learn from an over view of the in-situ visualization of the single-cell level in the TME of NSCLC and ovarian cancer archived FFPE tissue samples using the highly specific and sensitive RNAscope® in situ hybridization assay. They will also learn about the immune infiltration and state of lymphoid and myeloid cells in the TME by detecting key functional molecules.
Dr. Annelies Laeremans, a scientist with Advanced Cell Diagnostics will be the speaker for this event. Prior to joining Advanced Cell Diagnostics, Laeremans completed her postdoctoral studies in cancer biology at the University of California San Francisco before receiving her doctorate in cognitive and molecular neurosciences from the University of Leuven. She currently as a scientist in R&D at Advanced Cell Diagnostics.
LabRoots will host the webinar November 15, 2017, beginning at 10 a.m. PST. To learn more about this event, the speaker, or to register for free, click here.
About Advanced Cell Diagnostics
ACD - a Bio-Techne brand, shortens the path to personalized medicine and enables research, drug development and clinical applications by unlocking the power of RNA. ACD is a leader in the emerging field of molecular pathology, developing cell- and tissue-based research and diagnostic tests for personalized medicine.
Based in Silicon Valley, ACD’s products and pharma assay services are based on its proprietary RNAscope® technology, the first multiplex fluorescent and chromogenic in situ hybridization platform, capable of detecting and quantifying single molecules of RNA in situ. ACD has two product lines, namely RNAscope® and BaseScope™ consisting of assay reagent kits and 15,000+ off-the-shelf probes in addition to a Pharma Assay Services business which allow customers to run assays for their unique targets rapidly. Since its first launch in 2011, the technology boasts 1000+ citations, a new publication each day now, for single, duplex and multiplex RNA analysis.
LabRoots is the leading scientific social networking website, which provides daily scientific trending news, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.